Search results (1320)
« Back to PublicationsInhibiting the Priming for Cancer in Li-Fraumeni Syndrome.
Pantziarka P. and Blagden S., (2022), Cancers (Basel), 14
A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer
Fletcher CE. et al, (2022), Molecular Cancer, 21, 82 - 82
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.
COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: julian.knight@well.ox.ac.uk None. and COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium None., (2022), Cell, 185, 916 - 938.e58
Characterising 18F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging.
Scott NP. et al, (2022), Br J Cancer, 126, 598 - 605
The current status of risk-stratified breast screening.
Clift AK. et al, (2022), Br J Cancer, 126, 533 - 550
The immune landscape in BCR-ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy.
Strickland M. et al, (2022), Br J Haematol, 196, 1149 - 1158
When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers.
van Vugt MATM. and Parkes EE., (2022), Trends Cancer, 8, 174 - 189
Targeting MAPK in recurrent, low-grade serous ovarian cancer.
Blagden SP., (2022), Lancet, 399, 499 - 501
Targeting OXPHOS and the electronic transport chain in cancer; Molecular and therapeutic implications.
Greene J. et al, (2022), Semin Cancer Biol
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer.
Parkes EE. et al, (2022), Br J Cancer, 126, 247 - 258
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.
Long GV. et al, (2022), Ann Oncol, 33, 204 - 215
Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline.
Fox CP. et al, (2022), Br J Haematol, 196, 507 - 522
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy.
Booth S. et al, (2022), Br J Haematol, 196, 892 - 901
Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19.
Várnai C. et al, (2022), JAMA Netw Open, 5
Iron status influences the response of cord blood megakaryocyte progenitors to eltrombopag in vitro.
Liu Z-J. et al, (2022), Blood Adv, 6, 13 - 27
A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study.
Mead AJ. et al, (2022), Ther Adv Hematol, 13
A Review of the Prevention of Mother-to-Child Transmission of Human T-Cell Lymphotrophic Virus Type 1 (HTLV-1) With a Proposed Management Algorithm.
Barr RS. et al, (2022), Front Med (Lausanne), 9
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA).
Infante MS. et al, (2022), Front Oncol, 12
Defining disease modification in myelofibrosis in the era of targeted therapy
Pemmaraju N. et al, (2022), Cancer
Mutation agnostic diagnosis of clonal hematopoiesis of indeterminate potential (CHIP) using fluctuating methylation clocks
Schenck RO. et al, (2022), CANCER RESEARCH, 82